The Oncology Institute, Inc.
TOI
$3.31
$0.082.48%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 393.41M | 378.93M | 361.07M | 342.71M | 324.24M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 393.41M | 378.93M | 361.07M | 342.71M | 324.24M |
| Cost of Revenue | 339.42M | 325.19M | 305.72M | 285.27M | 264.67M |
| Gross Profit | 54.00M | 53.74M | 55.35M | 57.44M | 59.57M |
| SG&A Expenses | 107.83M | 111.17M | 112.69M | 113.49M | 113.87M |
| Depreciation & Amortization | 6.29M | 6.16M | 6.28M | 6.09M | 5.87M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 453.53M | 442.52M | 424.69M | 404.85M | 384.41M |
| Operating Income | -60.12M | -63.59M | -63.62M | -62.14M | -60.17M |
| Income Before Tax | -64.66M | -70.55M | -71.72M | -73.04M | -83.10M |
| Income Tax Expenses | -- | -314.00K | -179.00K | -80.00K | -36.00K |
| Earnings from Continuing Operations | -64.66 | -70.24 | -71.54 | -72.96 | -83.07 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -64.66M | -70.24M | -71.54M | -72.96M | -83.07M |
| EBIT | -60.12M | -63.59M | -63.62M | -62.14M | -60.17M |
| EBITDA | -53.83M | -57.43M | -57.34M | -56.05M | -54.29M |
| EPS Basic | -0.71 | -0.77 | -0.79 | -0.81 | -0.92 |
| Normalized Basic EPS | -0.54 | -0.60 | -0.61 | -0.62 | -0.57 |
| EPS Diluted | -0.72 | -0.78 | -0.80 | -0.82 | -0.93 |
| Normalized Diluted EPS | -0.54 | -0.60 | -0.61 | -0.62 | -0.57 |
| Average Basic Shares Outstanding | 300.16M | 297.98M | 295.92M | 295.29M | 294.51M |
| Average Diluted Shares Outstanding | 300.16M | 297.98M | 295.92M | 295.29M | 294.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |